CCELHealthcare · Medical Care FacilitiesCCEL Stock Forecast: Cryo-Cell International, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 19 Sept 2026 — inside the top quartile.
CCEL stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Cryo-Cell International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (98): Reported profit is backed by cash, and the company is not expanding recklessly.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
CCEL stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CCEL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 20 Oct 2025 | Maxim Group | Downgrade | Hold | — |
| 4 Mar 2025 | Maxim Group | Maintains | Buy | — |
| 29 Aug 2022 | Maxim Group | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CCEL appears on the weeks it earns a place.
CCEL vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 18 Sept 2026, Cryo-Cell International, Inc. returned −2.2% against +16.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CCEL analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Cryo-Cell International, Inc. (CCEL) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 475.0×
- Price / sales
- 1.1×
- Price / book
- −1.9×
- EV / EBITDA
- 46.0×
Cheaper than 2% of US stocks
Cheaper than 66% of US stocks
Cheaper than 95% of US stocks
Cheaper than 5% of US stocks
- Revenue growth (YoY)
- −1.9%
- Earnings growth (YoY)
- 55.9%
- Gross margin
- 78.4%
- Operating margin
- 15.4%
- Net margin
- −7.9%
Higher than 24% of US stocks
Higher than 76% of US stocks
Higher than 90% of US stocks
Higher than 73% of US stocks
Higher than 21% of US stocks
- Return on equity
- 13.1%
- Return on assets
- −0.1%
- Dividend yield
- 14.1%
Higher than 70% of US stocks
Higher than 43% of US stocks
Higher than 93% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Cryo-Cell International, Inc. (CCEL) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Cryo-Cell International, Inc. has a market value of $34.3M and an enterprise value of $40.1M.
Revenue in the twelve months to 31 May 2026: $31.2M. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: −$2.9M, a −9.2% net margin.
Free cash flow in the twelve months to 31 May 2026: $4.3M, after $114K of capital spending.
Cryo-Cell International, Inc. spent $1.2M on dividends in the twelve months to 31 May 2026.
Trailing P/E: 475.0×; forward P/E: 217.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 14.12%, paying out 0% of earnings.
Cryo-Cell International, Inc. employs 72 people — $434K of revenue per employee.
Data provided by Twelve Data
CCEL vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Cryo-Cell International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about CCEL stock
Is CCEL stock a buy right now?
Of the 1 analysts covering Cryo-Cell International, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Cryo-Cell International, Inc. 77 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CCEL?
As at 19 Sept 2026, Cryo-Cell International, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (98 of 100).
What is the CCEL stock forecast for 2030?
No analyst covering Cryo-Cell International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CCEL are extrapolating price history, which says nothing about the business.
How has CCEL stock performed over the past year?
Cryo-Cell International, Inc. returned -2.2% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Cryo-Cell International, Inc. do?
Cryo-Cell International, Inc. is a healthcare services company focused on cord blood and cord tissue banking.
About Cryo-Cell International, Inc.
Cryo-Cell International, Inc. is a healthcare services company focused on cord blood and cord tissue banking. The company provides cellular processing and cryogenic storage for family use, centered on the collection and preservation of umbilical cord blood and tissue stem cells. It also operates a public cord blood banking segment and manufactures PrepaCyte CB processing systems used in cord blood stem cell preparation. Through these offerings, Cryo-Cell serves expectant parents, healthcare professionals, and public donation programs, supporting long-term biological storage services and regenerative medicine research infrastructure. Headquartered in Oldsmar, Florida, Cryo-Cell International remains a specialized participant in the stem cell preservation market.
CEO Mr. David I. Portnoy · 72 employees · United States · https://www.cryo-cell.com